The bull case for Yellow Cake: its shares trade at a 30% discount to NAV, offering uranium exposure as nuclear capacity ...
Analyst rates Walmart a Hold: its scale and improving margins support a premium, while 44x forward earnings remains hard to ...
Analyst rates ADTRAN a Hold with a $5.40 target: optical growth alone cannot justify a higher multiple without margin and ...
Analyst rates Vistance Networks a Hold: repeated EBITDA guidance cuts and pressures outweigh its 0.72x forward EV/EBITDA.
Analyst rates Prenetics Global a Buy: its $13.30 FY 2027 target implies 29% upside; IM8 may generate 3:1 gross profit on ...
The following slide deck was published by Orion Energy Systems, Inc. in conjunction with this event.
The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with this event.
Analyst rates Atlas Copco a Hold: a 40% valuation premium at 30.8x earnings could limit returns and expose shares to declines ...
Analyst rates BTQ Technologies a Sell: after five revenue-free quarters, 2.3 quarters of cash mean one year of burn could ...
Analyst sees BlackRock as a better franchise, yet $1,101.72 leaves little cushion for lower profits; $63.30 2027 EPS supports ...
The bull case for Zimmer Biomet: at 9.66x forward EV/EBITDA, its transformation could drive share gains as China headwinds ...
Analyst rates Edgewise Therapeutics a speculative Buy with a ~$59 target, about 40% upside from $42, as cash supports a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results